Testim is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of testosterone.
As per the agreement, GSK has been granted the exclusive right to co-promote the sale of Testim with Auxilium in the US through 30 September 2015.
GSK will promote Testim to current Testosterone Replacement Therapy (TRT) prescribers, particularly primary care physicians, in the US.
Auxilium chief executive officer and president Adrian Adams said the collaboration expands the company’s reach to US physicians who treat men with low testosterone and its resulting symptoms, known as hypogonadism, which it believes is a prevalent, but poorly recognized condition.
"While the Auxilium sales force has consistently performed well in an increasingly competitive environment, adding the strength and breadth of GSK’s U.S. commercialization organization will further enhance our sales efforts with U.S. physicians who treat this condition," Adams said.
GSK Cardiovascular/Metabolic/Urology business unit vice president Cheryl MacDiarmid said, "We look forward to our collaboration with Auxilium and adding Testim to our portfolio so we can help meet the needs of men with this condition."
GSK is expected to start the promotion of Testim early in the third quarter of 2012, while Auxilium will remain responsible for all Testim commercial drug manufacturing, supply, and regulatory activities.